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Abstract
Since its discovery, nearly one decade of research on astrocyte elevated gene 1 (AEG-1) has witnessed expanding
knowledge of this molecule, ranging from its role in cancer biology to molecular mechanisms underlying the
biological functions. As a multifunctional oncoprotein, AEG-1 has been shown to overexpress in multiple types of
human cancer, and the elevation of AEG-1 in tumor cells leads to enhanced phenotypes characteristic of
malignant aggressiveness, including increased abilities to proliferate robustly, to invade surrounding tissues, to
migrate, to induce neovascularization, and to enhance chemoresistance. The multifunctional role of AEG-1 in tumor
development and progression has been found to be associated with several signaling cascades, namely, 1)
activation of NF-kappa B, partially through direct interaction with p65; 2) PI3K/AKT signaling triggered by AEG-1
indirectly; 3) enhancement of the transcriptional activity of beta-catenin by indirect activation of MAPK and
induction of LEF1; 4) regulation of mi/siRNA-mediated gene silencing by interacting with SND1; and 5) promotion
of protective autophagy; in addition to possibly unknown mechanisms. Elevated AEG-1 expression is seen in nearly
all tumor types, and in most cases AEG-1 positively correlates with tumor progression and poorer patient survival.
Taken together, AEG-1 might represent a potential prognostic biomarker and therapeutic target.
Discovery and molecule characteristics of AEG-1
In 2002 and 2004, several groups, under different
experimental settings, reported identification of the
gene, first named as astrocyte elevated gene 1 (AEG-1),
now having the GenBank symbol as MTDH, which
stands for metadherin, for its involvement in tumor
metastasis and adhesion. In an attempt to identifying
molecules involved in mediating HIV-related neuron
degeneration, Fisher’s group, by using subtraction hybri-
dization, found AEG-1 as a novel transcript induced by
HIV-1 infection or gp120 treatment in human fetal
astrocytes [1]. In another study by Brown and Ruoslahti
in 2004, phage display strategy was employed in a
mouse model of breast cancer metastasis, which
revealed that a gene identical to AEG-1 was expressed
at high levels in relation to metastasis of breast cancer,
and the identified gene was named metadherin after its
proposed role in promoting homing of breast cancer
cells to the lungs [2]. In the same year, Britt et al. and
Heidi et al., independently, identified that the same
molecule, this time designated LYRIC in both cases, was
a novel component of the tight junction structure of
epithelial cells [3] and an endoplasmic reticulum/nuclear
envelope-associated protein [4], respectively.
While the initial discovery of AEG-1 left with an
abundance of controversial understanding of its biologi-
cal functions and biochemical characteristics, which
remains elusive to date, a few features of AEG-1 have
been recognized with certain consensus. In human,
AEG-1 represents a protein of 582 amino acids, and the
amino acid sequences are highly conserved across verte-
brates. Despite its conservativeness, however, the three-
dimensional structure of AEG-1 has not been solved,
and the functional domains of the protein are not
clearly defined. To understand the biological functions
of AEG-1 in cells, however, its localization has been
investigated. In previously published studies, the intra-
cellular localization of AEG-1 appeared to be variable
and depend on the cell types examined and the imaging
techniques employed. In most cases both endogenous or
ectopically expressed AEG-1 is detectable in cytoplasm
as well as in the nucleus by immunohistochemical and
immunofluorescent staining of cultured cells or sec-
tioned specimens of tissues [4-7]. In rat liver, however,
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AEG-1 was displayed on cell membrane [3], whereas
GFP-fused AEG-1 showed stronger staining in the
nucleolus [8,9]. Three putative NLS has been predicted
in the lysine-rich regions of AEG-1 [4,6]. In the latter
report, interestingly, the functional importance of these
three regions was examined, and by using the GFP
reporting system, NLS 1 or 3 and their flanking regions
was shown to be able to target the reporter GFP peptide
to nuclear and nucleolus [9]. Moreover, as a protein
rich of the lysine residues, AEG-1 could be potential
subject to post-translational ubiquitination, SUMOlation
or acetylation [6]. There has been evidence indicating
potential mono-ubiquitination of AEG-1 in its NLS2
sequence and the flanking regions, and ubiqutinated
AEG-1 was found in the cytoplasm [9]. These observa-
tions might explain why AEG-1 of predicted 64 kD
molecule weight exhibits bands between 70-80 kD when
detected by antibodies raised against various AEG-1
immunogens fragments. Nevertheless, thus far the sig-
nificance of post-translational modification on the mole-
cular function of AEG-1 remains to be understood.
Elevated expression of AEG-1 in human cancers
and other conditions
Elevation of AEG-1 expression has been appreciated in a
spectrum of cancer types. Breast cancer, glioma and
prostate cancer were among the first tumor types in
which AEG-1 upregulation was recognized [6,7,10]. In
breast cancer, it has found that the degree of AEG-1
expression correlates with clinical staging and tumor-
node-metastasis (TNM) classification of the disease and
might be useful as a potential prognostic marker [7].
Through copy number variation/gene expression asso-
ciation analysis, AEG-1 has been identified as a metasta-
sis-associated gene whose overexpression is attributable
to genomic amplification in breast cancer [11]. In eso-
phageal squamous cell carcinoma, non-small cell lung
cancer and hepatocellular carcinoma, the level of AEG-1
upregulation also correlates with clinical progression
(staging) and poor prognosis of patients [12-14], further
suggesting that AEG-1 might function as an oncogenic
protein in various tumor types. Other tumor types in
which upregulation of AEG-1 has been demonstrated
include gastric cancer [15], colorectal carcinoma [16],
osteosarcoma [17].
It is of note that in other conditions than cancer,
altered expression of AEG-1 has also been reported. For
example, an allele of rs1835740 near the AEG-1 locus is
associated with migraine and increased AEG-1 expres-
sion [18]. Moreover, a recent study on the expression
pattern of AEG-1 has indicated a possible role of AEG-1
in the development of brain, liver and skin [19]. In addi-
tion, AEG-1 could be induced by LPS stimulation of the
U937 human promonocytic cells, suggesting a role of
the molecule in toll-like receptor-mediated signaling
[20].
AEG-1 overexpression in cancer has been attributed
to an increase in the amount of its transcript resulting
from one or both of two the following molecular
mechanisms. Firstly, high AEG-1 expression in breast
cancer and hepatocellular carcinoma is reportedly asso-
ciated with genomic amplification of the AEG-1 locus
[11,14]. The second mechanism, as suggested by several
studies on the transcriptional regulation of the gene, is
postulated based on the finding that AEG-1 mRNA is
inducible by several regulatory signals. Activation of the
Ras oncogene and subsequent induction of oncogenic
transcription factor c-MYC leads to recruitment of c-
MYC to the AEG-1 promoter region, which conse-
quently transactivates AEG-1 expression [21]. Further-
more, transcription suppressor PLZF has been found to
interact with AEG-1 and to facilitate the export of PLZF
from the nucleus to cytoplasm, thereby freeing a binding
region in the AEG-1 promoter/enhancer from the occu-
pancy by the suppressive PLZF, leading to increased
binding of transactivators, such as c-MYC, to its own
promoter [8]. This postulated model provides a rational
basis for the insight that a positive feedback loop might
exist to support AEG-1 overexpression in pathological
conditions. Pro-inflammatory factors including TNF-
alpha and LPS could induce AEG-1 in both tumor and
non-tumor cells [1,20]. While these stimuli are likely to
activate inflammation-stimulated transcription factors
such as NF kappa B and AP-1, the significance of AEG-
1 in mediating the reciprocal interaction between
inflammation and tumor development/progression
remains to be determined. For most tumor types, the
proportion of tumor samples with AEG-1 overexpres-
sion is significantly higher than that of those harboring
AEG-1 amplification. Hence, it would be of great inter-
est to further investigate whether cells harboring AEG-1
amplification seed a microenvironment that promotes
AEG-1 expression throughout tumor progression.
Biological functions of AEG-1
Interest in the effect of AEG-1 on the functions and the
malignant phenotype of cancer cells is emerging as a
hotspot in the field of cancer biology. Initial evidence
demonstrated that overexpressing AEG-1 subjected
breast cancer cells to lung homing [2], which was then
further confirmed by in vivo experiments [11]. Further-
more, AEG-1 was demonstrated to promote invasion
and migration of cancer cells. Emdad et al. first reported
that the NF kappa B pathway was required for AEG-1-
induced promotion of invasion of Hela cells in vitro [5].
In parallel, we found that AEG-1 promoted the invasion
of glioma cells in mouse with an in situ xenotranplan-
tion glioma model [22] through directly targeting and
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transactivating the promoter of MMP-9 gene, a mole-
cule broadly recognized to be a major metalloproteinase
required for ECM degradation and cytokine activation
of invading cells during the processes of tumor invasion
and metastasis, as well as other physiological and patho-
logical conditions [23].
Another oncologically important notion is the possible
involvement of AEG-1 in establishing chemoresistance,
a hallmark of tumor aggressiveness [24]. In breast can-
cer, elevated AEG-1 enables tumor cells to escape cell
death induced by paclitaxel, doxorubicin or cisplatin
[11]. In this model, AEG-1-induced chemoresistance
was thought to be mediated by survival-promoting
genes, most notably ALDH3A1 and c-MET. In the same
study, moreover, hydrogen peroxide-induced oxidative
stress could also be relieved by AEG-1 downstream
gene HOMOX1 [11]. Another investigation aimed to
identify regulators of 5-FU resistance gene showed that
AEG-1 promoted the expression of DPYD, the rate-lim-
iting enzyme of 5-FU degradation [25]. AEG-1 has been
shown to mediate upregulation of MDR1 via the PI3K/
AKT signaling and augmentation of translation [26], a
mechanism key to AEG-1-mediated efflux of doxorubi-
cin. It is also noteworthy that AEG-1 overexpression is
also associated with development of resistance in cells
against other types of stress, such as hypoxia and glu-
cose deprivation [27]. Moreover, evidence has shown
that AEG-1 could trigger protective autophagy, which is
a common mechanism employed by cancer cells to cope
with metabolic stress. Recent studies have shown that
by activating AMPK AEG-1 is able to elevate autophagy
regulator ATG5 and lead to increased autophagy [28].
AEG-1 also contributes to tumor growth through pro-
proliferative and anti-apoptotic effects. In prostate can-
cer [10] and breast cancer [29] elevation of AEG-1 has
been clearly linked to downregulation of cell cycle inhi-
bitors, leading to accelerated cell proliferation. Further-
more, in other models, AEG-1 has been found to be
sufficient to suppress apoptosis through a systematic
mechanism that upregulates apoptosis inhibitors via
activation of the PI3K/Akt signaling pathway [30].
In many tumor types that display elevated AEG-1
expression, AEG-1 has been shown to enhance tumor-
induced angiogenesis. In tumors formed by AEG-1-
transduced rat embryo fibroblasts, intensive angiogenic
markers including Ang-1, HIF1 alpha and CD31 are cor-
related with AEG-1 upregulation. It appears that the
PI3K/AKT signaling is involved in AEG-1 induced
angiogenesis [31]. Interestingly, in addition to its role in
promoting the pro-angiogenic activity of tumor cells,
endothelial AEG-1 might also be able to enhance the
capability of vascular endothelial cells to form neovascu-
larture, as ectopic expression of AEG-1 in HUVEC cells
was found to result in increased tube formation [31].
Moreover, analysis of clinical samples taken from large
cohorts of patients of breast cancer showed that AEG-1
correlated positively with the VEGF level and the micro-
vascular density [32].
Activation of oncogenic signal cascades by AEG-1
The molecular mechanisms underlying the oncogenic
role of AEG-1 in human cancers has been studied dur-
ing this decade. There has been a large abundance of
evidence demonstrating that several major cellular sig-
naling cascades might be associated with the ability of
AEG-1 to execute the identified biological functions in
various contexts. The NF kappa B pathway was first
reported to be activated by AEG-1 through physical
interaction with the p65 subunit of NF kappa B complex
[5], with further evidence revealing that binding of
AEG-1 to p65 resulted in recruitment of acetyltransfer-
ase CBP to p65, which might contribute to transcrip-
tional activation [33]. It is believed that depending on
the residue sets that are acetylated, the affinity with
which p65 binds to I kappa B alpha can be increased or
decreased, and thus the transcription activity of p65 is
activated or inhibited correspondingly [34]. In the sce-
nario of p65 activation induced by AEG-1, whether the
recruitment of CBP results in acetylation of transactivat-
ing residues of p65 or alternatively other component(s)
of the p65-containing complex that occupies the target
promoter remains to be elucidated.
As aforementioned, in the attempt to understand the
molecular mechanism that mediates the expression of
AEG-1, the PI3K/AKT was identified to be required for
Ras-induced AEG-1 expression [21]. Interestingly, the
same study found that AKT was also a downstream
mediator of the functions of AEG-1, as overexpression
or silencing of AEG-1 resulted in elevation or attenua-
tion, respectively, of the phosphorylation status of AKT
[10,29,30]. Activation of AKT by AEG-1 led to phos-
phorylation of GSK3-beta and phosphorylation suppres-
sion of FOXO1/3 activity, resulting in enhanced cell
survival and proliferation [10,29,30]. Given that PI3K/
AKT signaling represents a commonly activated onco-
genic pathway in various cancers and crosstalks with
multiple signaling pathways, including NF kappa B [35],
it is likely that AKT activation could further enhance
the activation NF kappa B induced by AEG-1. In hepa-
tocellular carcinoma, AEG-1 has been shown to increase
phosphorylation of MAPK molecules, including ERK1/2
and p38, which subsequently activates Wnt-mediated
signaling and consequently leads to increased tumor
angiogenesis [14].
Interaction of AEG-1 with other proteins and the sub-
sequent signaling effects remain to be understood.
While several signaling pathways involved in mediating
the oncogenic functions of AEG-1 have been elucidated,
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little is known about what direct interactions occur
between AEG-1 and other proteins and how they contri-
bute to the downstream effects of AEG-1.
Engagement of AEG-1 in the RNA-induced
silencing complex (RISC)
Recent reports by two independent groups have shown
that AEG-1 could interact with components of the RISC
complex. By employing yeast two-hybrid method, co-
immunoprecipitation and mass-spectrometry, SND1 of
the RISC complex was identified as a novel binding
partner of AEG-1 [36,37]. SND1 was initially dentified
as a transcription co-activator interacting with viral
transcription factor EBNA2 [38] and as an activator of
c-Myb [39] and STAT6 [40]. It was later reported to be
contained in the RISC complex [41] and thus important
for the editing and subsequent degradation of dsRNA
[42]. Disruption of SND1 in C. elegance results in
defects in the action of siRNA [41], which underscores
its importance in RNAi-induced gene silencing. As
AEG-1 has been demonstrated to interact with SND1
and enhance the activity of RISC [36], it increases degra-
dation of tumor suppressor mRNAs that are target of
onco-miRs [37]. What remains interesting is that AEG-1
mediated-activation of RISCs appears to be a general
observation for all RISCs in cells with high AEG-1
expression, and yet it is unclear whether the net onco-
genic effects of microRNAs documented in cancer cells
are due to a selective interaction between AEG-1 and
onco-miR-containing RISCs. Alternatively, AEG-1 may
facilitate the function of all RISCs in a non-selective
manner, and the oncogenic effects of microRNAs merely
result from the fact that tumor cells harbor onco-miRs
at higher levels than those of tumor suppressive micro-
RNAs. Nevertheless, despite that the significance of the
interactions between AEG-1 and RISC demands further
investigation, the finding of AEG-1 as a component of
RISC might provide new insights in how AEG-1 pro-
motes a wide variety of oncogenic activities at a highly
context-dependent fashion. To understand how AEG-1
affects RISC activity, studies on whether AEG-1 could
regulate RNA recognition or cleavage activity are
essential.
Summary and perspectives
Accumulating evidence has shown that AEG-1 plays
remarkable roles in the regulation of various physiologi-
cal and pathological processes [43]. A model presented
as Figure 1 attempts to illustrate possible molecules and
pathways that have been suggested by mechanistic stu-
dies to mediate the biological functions of this impor-
tant protein. Although a great abundance of literature
has documented an array of cellular functions associated
with altered expression level of AEG-1, we are yet far
from revealing the biological significance of this mole-
cule in physiological and pathological conditions.
Experimental evidence from AEG-1 knockout or trans-
genic animal models would be important for further
understanding of the functional significance of AEG-1
in embryonic development and diseases. Evolutionally,
AEG-1 is only found in vertebrates that have complete
immune systems developed, and it is noteworthy that
the signaling pathways identified thus far modulated by
AEG-1 have also been associated with the regulation of
inflammation and immune response. It is thus of impor-
tance to further investigate the significance of aberrated
AEG-1 expression in pathogenesis related to abnormal
immune response or nonresolving inflammation, such as
cancer, autoimmune diseases and severe immunopatho-
logical conditions caused by pathogen infection. At the
molecule level, evidence is still needed to illustrate
whether AEG-1 exerts its biological function by bio-
chemically modifying its binding partners or alterna-
tively, by acting as a scaffold of the signaling/effector
complex. Moreover, the biochemical modification occur-
ring to AEG-1 itself is also of great interest for further
investigation, as such modification(s), if proved to be
functionally important for AEG-1, would be potentially
promising targets for optimal inhibitors or therapeutic
drugs against diseases involving upregulated or over-
activated AEG-1, including cancer.
AEG-1 is also under investigation and development
for its potential value as a diagnostic or prognostic bio-
marker based on its overexpression and correlations
with disease staging and outcome throughout a wide
range of cancer types. Yet for the latter application,
however, larger cohorts of patient studies and
Figure 1 A model illustrating the biological functions and
possible underlying molecular mechanisms of AEG-1. Dashed
arrows indicate indirect molecular effects.
Ying et al. Cell & Bioscience 2011, 1:36
http://www.cellandbioscience.com/content/1/1/36
Page 4 of 6
prospective investigation on the correlation of AEG-1
mRNA or protein in blood, urine and biopsy samples
with clinical characteristics are urgently needed.
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